Increasing white blood cell count
Pro Research Analysisby 
Searched over 200M research papers
Pharmacological Agents for Increasing White Blood Cell Count
Several pharmacological agents have been shown to effectively increase white blood cell (WBC) counts. Mavorixafor, an oral CXCR4 antagonist, has demonstrated the ability to increase total WBCs and their subsets (neutrophils, lymphocytes, monocytes) by 1.5- to 3-fold in various patient populations, including those with WHIM syndrome, Waldenström's macroglobulinemia, and clear cell renal cell carcinoma. These increases were rapid, sustained during chronic treatment, and more pronounced in patients with pre-existing cytopenia. Mavorixafor was generally well tolerated and also associated with a reduction in infection rates in WHIM syndrome patients .
Another compound, 12-O-tetradecanoylphorbol-13-acetate (TPA), has been used intravenously to increase depressed WBC and neutrophil counts in cancer patients undergoing chemotherapy. In these patients, WBC and neutrophil counts nearly doubled within a few days of TPA administration, with effects lasting at least three days and only mild, reversible side effects observed .
Pegbovigrastim, a granulocyte colony-stimulating factor analog, has been shown to increase WBC, neutrophil, lymphocyte, and monocyte counts in dairy cows, regardless of parity. It also reversed the negative effects of high prepartum non-esterified fatty acid concentrations on WBC counts, suggesting its potential to counteract metabolic stress-induced leukopenia .
Corticosteroids and Catecholamines: Mechanisms and Clinical Effects
Corticosteroids, such as dexamethasone, are well known to cause leukocytosis. In hospitalized patients without infection or malignancy, high-dose corticosteroids can increase WBC counts by up to 4.84 × 10⁹/L within 48 hours, with the effect being dose-dependent. Increases beyond this range or after low-dose steroids may indicate other causes of leukocytosis .
The mechanism behind steroid-induced leukocytosis involves demargination, where leukocytes move from the vascular wall into the main circulation. This process is also triggered by catecholamines like epinephrine. Recent research shows that both glucocorticoids and catecholamines cause leukocyte softening, which facilitates their movement into the bloodstream, leading to a rapid and significant increase in clinical WBC counts .
Lifestyle and Physiological Factors Affecting White Blood Cell Count
Cigarette smoking is a significant and reversible cause of elevated WBC count. Current smokers have higher WBC counts, including all major subtypes, compared to non-smokers. Smoking cessation leads to normalization of WBC counts within a year, and this effect is sustained for at least two more years .
Depression has also been found to causally increase overall WBC and basophil counts, with a marginal effect on lymphocytes. Conversely, higher monocyte counts may offer some protection against depression, though this association is less certain .
Clinical and Surgical Contexts
In the context of lung transplantation surgery with veno-arterial extracorporeal membrane oxygenation (V-A ECMO), higher WBC counts are associated with an increased requirement for unfractionated heparin to maintain target clotting times. This suggests that WBC count may be a useful marker for adjusting anticoagulation therapy during such procedures .
Implications for Disease Risk and Immune Function
Higher counts of certain WBC subtypes, such as eosinophils and lymphocytes, have been associated with a reduced risk of colorectal cancer, suggesting a protective role for these immune cells in cancer development .
Conclusion
White blood cell counts can be increased through various pharmacological agents, including CXCR4 antagonists, TPA, and colony-stimulating factors, as well as by physiological responses to corticosteroids and catecholamines. Lifestyle factors like smoking and psychological states such as depression also influence WBC levels. Understanding these mechanisms and influences is important for clinical decision-making, especially in contexts where WBC count is a critical marker of immune function or treatment response Dale2021Sullivan2025Cao2025+6 MORE.
Sources and full results
Most relevant research papers on this topic